Table 3.
Impact of ELR and ENLR on overall survival (OS): Kaplan Meier survival analysis, univariate and multivariate Cox regression (models for ELR and ENLR, respectively), n = 163
| Variables | Kaplan-Meier survival analysis | UNIVARIATE Cox regression | MULTIVARIATE Cox regression for ELR ≥ 0.1 model | MULTIVARIATE Cox regression for ENLR ≥0.5 model | ||||
|---|---|---|---|---|---|---|---|---|
| X2 | p-value | HR (IC 95%) | p-value | HR (IC 95%) | p-value | HR (IC 95%) | p-value | |
| Age ≥ 65 years (vs. < 65 years) | 3.9 | 0.047 | 2.6 (0.98–6.7) | 0.055 | 2.8 (1.0–8.2) | 0.059 | 2.8 (1.03–7.8) | 0.043 |
| FIGO advanced stage III (vs. stage I-II) | 8.3 | 0.004 | 3.4 (1.4–8.4) | 0.007 | 3.1 (0.9–9.8) | 0.060 | 2.8 (0.9–8.5) | 0.065 |
| Tumour grade 3 (vs. grade 1–2) | 15.8 | 0.000 | 8.1 (2.4–27.4) | 0.001 | 6.8 (1.9–24.7) | 0.003 | 5.8 (1.6–21.2) | 0.007 |
| Endometroid histology (vs. other histology) | 10.1 | 0.001 | 0.3 (0.1–0.63) | 0.003 | 0.4 (0.1–1.1) | 0.068 | 0.4 (0.14–1.2) | 0.099 |
| ESMO-ESTRO-ESGO High Risk groups 4–6 (vs. groups 1–3) | 7.4 | 0.007 | 4.7 (1.4–15.8) | 0.014 | 1.2 (0.2–6.5) | 0.856 | 1.3 (0.2–6.9) | 0.770 |
| ELR ≥ 0.1 (vs. < 0.1) | 6.3 | 0.004 | 2.9 (1.2–6.8) | 0.017 | 4.9 (1.9–12.4) | 0.001 | – | – |
| ENLR ≥ 0.5 (vs. < 0.5) | 6.6 | 0.010 | 3.0 (1.2–7.3) | 0.015 | – | – | 3.9 (1.6–9.8) | 0.003 |
All entries in boldface reflect p-values < 0.05